CA2060384C - Methode therapeutique - Google Patents

Methode therapeutique

Info

Publication number: CA2060384C
Authority: CA; Canada
Prior art keywords: antibody; treatment; campath; use according; cdw52 antigen
Prior art date: 1991-10-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2060384

Other languages

English (en)

Other versions

CA2060384A1 (fr

Inventor

Geoffrey Hale

Herman Waldmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BTG International Ltd

Original Assignee

BTG International Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-15

Filing date

1992-01-30

Publication date

2001-06-12

1992-01-30 Application filed by BTG International Ltd filed Critical BTG International Ltd

1993-04-16 Publication of CA2060384A1 publication Critical patent/CA2060384A1/fr

2001-06-12 Application granted granted Critical

2001-06-12 Publication of CA2060384C publication Critical patent/CA2060384C/fr

2012-01-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010065524 CD52 Antigen Proteins 0.000 title claims abstract description 13
102000013135 CD52 Antigen Human genes 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
238000011282 treatment Methods 0.000 claims abstract description 38
230000001404 mediated effect Effects 0.000 claims abstract description 17
206010061218 Inflammation Diseases 0.000 claims abstract description 16
230000004054 inflammatory process Effects 0.000 claims abstract description 16
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 15
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 10
210000001258 synovial membrane Anatomy 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 12
150000003431 steroids Chemical class 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 4
230000003356 anti-rheumatic effect Effects 0.000 claims 1
241001465754 Metazoa Species 0.000 abstract description 7
238000000034 method Methods 0.000 abstract description 4
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 6
241000282412 Homo Species 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
102100024217 CAMPATH-1 antigen Human genes 0.000 description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
229930105110 Cyclosporin A Natural products 0.000 description 4
108010036949 Cyclosporine Proteins 0.000 description 4
101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 4
229960001265 ciclosporin Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000001503 joint Anatomy 0.000 description 4
230000004044 response Effects 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 3
230000005784 autoimmunity Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
206010053240 Glycogen storage disease type VI Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000003435 antirheumatic agent Substances 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000011443 conventional therapy Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229960001639 penicillamine Drugs 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010020633 Hyperglobulinaemia Diseases 0.000 description 1
208000003623 Hypoalbuminemia Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010035623 Pleuritic pain Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000011366 aggressive therapy Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001886 cortisols Chemical class 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
-1 for example Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000013101 initial test Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000011862 kidney biopsy Methods 0.000 description 1
238000009940 knitting Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012317 liver biopsy Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229940090008 naprosyn Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
238000010926 purge Methods 0.000 description 1
SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
229960004986 pyritinol Drugs 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2060384 1991-10-15 1992-01-30 Methode therapeutique Expired - Lifetime CA2060384C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77559891A	1991-10-15	1991-10-15
US07/775,598		1991-10-15

Publications (2)

Publication Number	Publication Date
CA2060384A1 CA2060384A1 (fr)	1993-04-16
CA2060384C true CA2060384C (fr)	2001-06-12

Family

ID=25104897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2060384 Expired - Lifetime CA2060384C (fr)	1991-10-15	1992-01-30	Methode therapeutique

Country Status (2)

Country	Link
CA (1)	CA2060384C (fr)
ZA (1)	ZA927925B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116785434A (zh) *	2023-03-29	2023-09-22	暨南大学附属第一医院（广州华侨医院）	一种cd52+巨噬细胞作为骨关节炎治疗靶点的应用

1992
- 1992-01-30 CA CA 2060384 patent/CA2060384C/fr not_active Expired - Lifetime
- 1992-10-14 ZA ZA927925A patent/ZA927925B/xx unknown

Also Published As

Publication number	Publication date
ZA927925B (en)	1994-04-14
CA2060384A1 (fr)	1993-04-16

Legal Events

Date	Code	Title	Description
1992-05-14	EEER	Examination request
2012-01-30	MKEX	Expiry

Publication	Publication Date	Title
US6120766A (en)	2000-09-19	CDW52-specific antibody for treatment of multiple sclerosis
KR100575069B1 (ko)	2006-05-02	역적응성 면역 반응, 특히 이식 거부반응을 예방하기 위한ｃｄ40:ｃｄ154 결합 저해제의 용도
JP4694784B2 (ja)	2011-06-08	慢性関節炎の処置
RU2607022C2 (ru)	2017-01-10	Способы и композиции для лечения волчанки
US20200079871A1 (en)	2020-03-12	Treatment for multiple myeloma (mm)
CZ244499A3 (cs)	1999-10-13	Použití sloučeniny anti-CD40L pro výrobu léku pro léčení imunokomplexových poškození
US20250263480A1 (en)	2025-08-21	Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant
EP0222617A2 (fr)	1987-05-20	Thérapie par anticorps monoclonal
WO2007119447A1 (fr)	2007-10-25	Agent thérapeutique pour la polyarthrite rhumatoïde
EP1047449B1 (fr)	2003-09-10	Compositions et procedes immunologiques utilises pour modifier provisoirement la myeline du systeme nerveux central des mammiferes afin de stimuler la regeneration neuronale
EP0610447B1 (fr)	1998-12-16	UTILISATION D'UN ANTICORPS DIRIGE CONTRE LE CDw52 POUR LE TRAITEMENT D'UNE INFLAMMATION DES ARTICULATIONS INDUITE PAR LES LYMPHOCYTES T
CA2060384C (fr)	2001-06-12	Methode therapeutique
Stevenson et al.	1985	Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells
WO2021018191A1 (fr)	2021-02-04	Méthode de traitement d'une maladie auto-immune par un antagoniste de l'il-17
HK1011618B (en)	2000-04-28	Cdw52-specific antibody for treatment of multiple sclerosis
HK1255653B (en)	2025-03-14	Methods and compositions for treating lupus
HK1255653A1 (en)	2019-08-23	Methods and compositions for treating lupus